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The Influence of BIBW22BS, a Dipyridamole Derivative, on the 
Antiproliferative Effects of 5Fluorouraci1, Methotrexate and 
Gemcitabine In vitro and in Human Tumour Xenografts 
W. J.M. Jansen,’ H.M. Pinedo,’ CL. van der Wilt,’ N. Feller,’ U. Bamberger2 and E. Boven’ 
‘Department of Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; 
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Dipyridamole is known as a potent inhibitor of facilitated diffusion-mediated nucleoside transport as well as a 
modulator of ‘classical’ multidrug resistance. BIBW22BS, a derivative of dipyridamole, has been found to be 20- 
to lOO-fold more potent in the reversal of multidrug resistance when compared to the parent compound. In 
parallel, we studied the efficacy of BIBW22BS in the modulation of the antiproliferative effects of 54luorouraci1, 
methotrexate and gemcitabine in human cancer cell lines. BIBW22BS, at non-toxic concentrations up to 1.0 /AM, 
increased the antiproliferative effects of 54uorouracil2- to 6-fold in seven of the eight colon cancer cell lines 
tested in a dose-dependent manner. The addition of 1.0 PM BIBWZZBS to methotrexate resulted in a slight 
increase in the antiproliferative effects, but inhibited the activity of gemcitabine 30- to loo-fold in various cancer 
cell lines. In vitro, no notable difference was found between BIBWZZBS and dipyridamole in their capacity to 
modulate the activity of the antimetabolites studied. BIBWZZBS did not affect the growth inhibition induced by 5- 
lluorouracil or gemcitabine in human tumour xenografts grown subcutaneously in nude mice. We confumed the 
higher potency of BIBW22BS when compared to dipyridamole in the reversal of drug resistance in the Pgp- 
positive COLO 320 cell line. 
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INTRODUCTION 
BIOCHEMICAL MODULATION of the activity of antimetabolites has 
been the subject of clinical trials to improve the outcome of 
cancer chemotherapy. In the laboratory, dipyridamole has been 
shown to inhibit facilitated diffusion-mediated nucleoside trans- 
port and, by blockage of nucleoside salvage, to enhance the 
antiproliferative effects of methotrexate, N-phosphonacetyl-L- 
aspartate (PALA) and acivicin. In addition, dipyridamole can 
also increase the toxicity of S-fluorouracil, although interference 
with thymidine salvage did not appear to be a critical factor [ 11. 
Grem has described an alteration of Sfluorouracil metabolism 
by dipyridamole, producing a selective increase in fluorodeoxy- 
uridine monophosphate (FdUMP) levels by a decrease of the 
efflux of fluorodeoxyuridine. 
The modulating capacity of dipyridamole when combined 
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with 5-fluorouracil or methotrexate has been further studied in 
phase I clinical trials [2, 31. Dipyridamole did not affect the 
clinical toxicity, but promoted the total body clearance of 5- 
fluorouracil[3]. Dipyridamole did not alter the pharmacokinet- 
its of methotrexate, but the toxicity was potentiated, possibly as 
a result of interference with thymidine salvage which is necessary 
for normal physiological processes [2]. Due to high protein 
binding, the steady state concentration of free dipyridamole 
given by continuous infusion at the maximum tolerated concen- 
tration was 2&25 nM and this would be expected to have 
minimal effect considering in vim data on nucleoside transport 
inhibition [ 11. More potent derivatives of dipyridamole may be 
more effective at increasing the efficacy of S-fluorouracil and 
methotrexate. 
BIBWZZBS, 4-[N-(2-hydroxy-2-methyl-propyl)-ethanolam- 
ino]-2,7-bis(cis-2,6-dimethyl-morpholino)-6-phenylpteridine, is 
a dipyridamole derivative and, similar to the parent compound, 
a bifunctional modulator. BIBWZZBS was reported to have a lo- 
fold higher potency than dipyridamole in the enhancement 
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of the antiproliferative effects of S-fluorouracil [4]. We have 
previously shown that BIBWZZBS is 20- to lOO-fold more potent 
than the parent compound in the reversal of multidrug resistance 
in cancer cells that express P-glycoprotein (Pgp) [ 51. 
In the current experiments, we compared the modulating 
effects ofBIBW22BS and dipyridamole on S-fluorouracil, metho- 
trexate and gemcitabine in a series of human cancer cell lines in 
vitro. In addition, we measured cellular free fluorodeoxyuridine 
monophosphate (FdUMP) levels after cells were exposed to 5- 
fluorouracil with or without the modulators. The effect of 
BIBWZZBS on the antitumour activity of 5-fluorouracil or 
gemcitabine was studied in human tumour xenografts. 
MATERIALS AND METHODS 
Cell lims and characteristics 
Various human cancer cell lines were used in the in vitro 
experiments (Table 1). Cells were grown in Dulbecco’s modified 
Eagle’s medium (Gibco, Breda, The Netherlands) supplemented 
with 10% heat-inactivated fetal calf serum (FCS; Sanbio, Uden, 
The Netherlands), 50 IU/ml penicillin and 50 kg/ml strepto- 
mycin (Flow, Irvine, Scotland) in a humidified atmosphere 
containing 5% CO2 at 37°C. Cells were screened for Mycoplasma 
contamination by using a rapid detection system with a 3H- 
labelled DNA probe (Gen-Probe, San Diego, California, 
U.S.A.) and were found to be negative. 
Cells were characterised for the presence of a variety of 
antigens. The polyclonal rabbit (YCEA antibody (1 : loo), 
directed against the carcinoembryonic antigen, was obtained 
from Dakopatts (Glostrup, Denmark). Monoclonal antibody 
JSB-1 (1 : 100) was used to detect Pgp [6]. The monoclonal 
antibody E48 (10 kg/ml), directed against a M, 22,000 desmo- 
somal glycoprotein, was used as a negative control [7]. For 
immunocytochemistry, cells were spun on slides, air-dried for 
1 h and then fixed for 15 min in cold (4°C) acetone. Immunostain- 
ing was done with the Histostain-SP kit (Zymed, Burlingame, 
California, U.S.A.). The intensity of staining was expressed as 
Table 1. Human cancer cell lines and characteristics 
Antigen expressionS 
Cell line T,* MDRlf JSB-1 uCEA E48 
Colon cancer 
COLO 205 40 0 + (100%) - 
COLO 320 39 2.97 + (50%) + (100%) - 
SW1398 59 1.91 ++ (80%) + (90%) - 
SW1116 49 0.10 2 (15%) 2 (40%) - 
LS174T 31 0.50 c (5%) ++ (30%) - 
HT29 35 0 - + (95%) - 
LOVO 31 0.10 + (10%) + (95%) - 
WiDr 32 0 - + (95%) - 
Ovarian cancer 
A2780 55 0 - -- 
IGROV-1 39 0 - -- 
Breast cancer 
MCF-7 38 0 - -- 
*T,, population doubling time in tirro in h. tMDR1 gene expression as 
determined by the RNAse protection assay; the expression of MDRl 
samples is relative to the KB-8-5 cell line set at 1.0. *Antigen expression 
as determined by immunocytochemistry; ++ strong, + moderate, 2 
weak and - no staining; numbers in parentheses are the percentage of 
stained cells. 
strong (+ +), moderate (+), weak (t) or negative (-). The 
percentage of stained cells was also determined. 
The expression of the MDRZ gene was measured with the 
RNAse protection assay. The RNA was isolated from subcon- 
fluent cells using a NP40 lysis mix followed by centrifugation to 
separate membranes and nuclei from cytosol. RNAse protection 
was performed as described earlier [5]. Briefly, 10 pg of total 
RNA was hybridised with a [32P]CTP-labelled anti-sense RNA 
probe, specific for MDRZ-mRNA, which was obtained by 
transcription of a 301 nucleotide cDNA fragment (positions 
3500-3801) with SP6 RNA polymerase. A y-actin’probe was 
included as an internal control for determination of RNA 
loading. The hybridised probe was visualised after electrophor- 
esis through a denaturing 6% acrylamide gel. For autoradiogra- 
phy, the gel was exposed at - 70°C to a Kodak XS fihn overnight. 
The results were calculated as the expression of MDRZ samples 
relative to the MDRZ expression in the multidrug-resistant KB- 
8-5 cell line, which was set at 1.0. 
Drugs 
5-Fluorouracil (Multipharma, Weesp, The Netherlands) was 
purchased as a solution of 50 mgiml and methotrexate 
(Pharmachemie, Haarlem, The Netherlands) as a solution of 
2.5 mg/ml. Gemcitabine was donated by Eli Lilly (Indianapolis, 
Indiana, U.S.A.) as a powder and was dissolved in 0.9% NaCl 
to a final concentration of 10 mg/ml. Doxorubicin (Farmitalia 
Carlo Erba, Nivelles, Belgium) was dissolved in water at a 
concentration of 2 mgiml. Vincristine (Eli Lilly, Amsterdam, 
The Netherlands) was purchased as a solution of 1 mg/ml. 
BIBW22BS and dipyridamole (both from Dr Karl Thomae 
GmbH, Biberach, Germany) were first dissolved in 0.1 N HCl 
and then diluted in 0.9% NaCl to a final concentration of 2 mM 
at pH 2.7. Drugs were further diluted in tissue culture medium 
when investigated for the antiproliferative ffects in vitro. 
Drug sensitivity in vitro 
Cellular drug sensitivities were measured with the MTT assay 
[8]. Cells were harvested with 0.2% EDTA or 0.25% trypsin 
plus 0.2% EDTA to obtain a single cell suspension. Cells were 
seeded in 100 ~1 tissue culture medium in 96-well microtitre 
plates at 5000 cells/well, except for A2780 at 3000 cells/well. The 
plates were incubated under standard conditions for 24 h. Drugs 
were added to achieve a final volume of 200 ~1. The cells were 
then cultured for another 96 h. Thereafter, the medium was 
removed and 50 ~1 MTT (Sigma) in phosphate buffered saline 
(0.4 mg/ml) were added. The plates were incubated for an 
additional 2-3 h and 200 p,l dimethylsulphoxide (DMSO) with 
0.5% FCS were added to dissolve the formazan crystals. The 
optical density was read on a Labsystems Multiskan Bichromatic 
plate reader (Labsystems OY, Helsinki, Finland) at 540 nm. All 
drug concentrations were tested in four replicate wells and each 
experiment was performed in triplicate. The antiproliferative 
effects were expressed as the IC 50, which is the concentration of 
the drug inducing 50% growth inhibition when compared to 
the growth of control cells. The results were expressed in a 
modulation factor (potentiation or inhibition) based on the xcso 
of the cells treated with the drug alone and that of cells treated 
with the drug and the modulator. 
The influence of protein binding of both modulators on the 
antiproliferative effects of 5-fluorouracil was analysed in the 
COLO 205 cell line. Various concentrations of human serum 
albumin (final concentration 25 or 35 g/l) or normal human 
serum (final concentration 10 or 40%) were added to tissue 
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culture medium not containing FCS. The assay was carried out 
as described above. 
Determination of free FdUMP 
The determination of free FdUMP was based on an isotope- 
dilution assay of [6-3H] FdUMP binding to L. casei thymidylate 
synthase [9] and modified by Van der Wilt and associates [lo]. 
Cells in samples of 1 X 107/ml were incubated with 10 ~.LM 
S-fluorouracil with or without 1 PM BIBWZZBS or dipyridam- 
ole for 4 h at 37°C. Thereafter, the cell pellets were denatured 
with the addition of trichloroacetic acid (final concentration of 
8%) and subsequently neutralised with alamine/freon (1 : 2). 
The denatured suspensions (75 (~1) were incubated with 10 ul 
12 nM [6-3H] FdUMP, 10 ~1 L. casei thymidylate synthase and 
10 ~1 TRIS buffer in a Snal volume of 105 p.1. To provide a 
standard curve, 10 l~,l FdUMP (concentration range from 0.01 
to 0.5 pM) were added to a number of samples. After an 
incubation period of 2 h at 30°C the samples were prepared for 
liquid scintillation counting. A ratio was calculated between the 
samples with mixed radiolabelled and cold FdUMP (standard 
curve) and the samples with only radiolabelled FdUMP. The 
standard curve of concentration against ratio provided a quantit- 
ation for the free FdUMP concentration (fmol/107 cells) in the 
samples. 
Drug sensitivity in vivo 
Female nude mice (Hsd:athymic nude-nu) were purchased at 
the age of 6 weeks (Harlan CPB, Zeist, The Netherlands). The 
animals were maintained in isolation and animal handling was 
carried out under sterile conditions. The COLO 205, WiDr and 
A2780 xenografts were established from cell lines grown in tissue 
culture medium. Mice were inoculated subcutaneously with 
1 X lo7 cells in both flanks. The solid tumours arising at the 
inoculation site (passage 1) were transferred as tissue fragments 
with a diameter 2-3 mm through a small skin incision into both 
flanks of 8- to lo-week old mice. Treatment experiments were 
carried out in passage 2or higher. 
The COLO 205, WiDr and A2780 xenografts were measured 
twice a week in three dimensions with a slide caliper. The 
volume was calculated by the equation 
length x width x thickness x 0.5, and expressed in mm3. At 
the start of treatment (day 0), groups of five-six tumour- 
bearing mice were formed to provide a mean tumour volume 
of approximately 100 mm3 in each group. For in vivo use, 
BIBWZZBS was dissolved in 0.1 N HCI at a concentration of 
20 mg/ml and further diluted in 0.9% NaCl to 2.5 mg/ml at 
pH 2.7. The modulating capacity of BIBWZZBS was determined 
by administration of BIBWZZBS 50 mg/kg intravenously (i.v.) 
followed after 1 h by S-fluorouracil 60 mg/kg intraperitoneally 
(i.p.) at days 0,7, 14 and 2 1 or by gemcitabine 240 mgikg i.p. at 
days 0 and 7. The maximum tolerated doses of 5-fluorouracil 
[ll] and gemcitabine [12] were based on the occurrence of a 
mean weight loss of approximately 10% of the initial weight 
within 1 week after the first injection. The maximum tolerated 
dose of BIBWZZBS of 50 mgikg i.v. and the interval of 1 h 
between the modulator and the antimetabolites were deduced 
from earlier experiments in multidrug-resistant human tumour 
xenografts [5]. We selected the schedule because in the first 4 h 
after administration of BIBWZZBS at a dose of 12.5 mg/kg 
i.v., mouse plasma levels were considered to be sufficient for 
modulation with reference to modulating concentrations in vitro. 
For the evaluation of drug efficacy, the tumour volume was 
expressed by the formula VT/V,, where V, is the volume at any 
given day and V, is the volume at day 0. The ratio of the mean 
relative volume of treated tumours over that of control tumours 
multiplied by 100% (T/C%) was assessed at each day of measure- 
ment. Antitumour effects were expressed as the percentage 
of growth inhibition (lOO%-7X%) and differences between 
groups were evaluated with Student’s r-test. 
RESULTS 
First, the human cancer cell lines were characterised for 
growth, antigen expression and the presence of the MDRI gene. 
The results are summarised in Table 1. In five of the eight colon 
cancer cell lines, Pgp expression was detected with the JSB-1 
antibody and the RNAse protection assay confirmed the presence 
of the MDR I gene. 
The eight colon cancer cell lines were used to determine 
the efficacy of BIBWZZBS in the modulation of 5-fluorouracil 
antiproliferative ffects in vitro. For BIBWZZBS, the ICKY in the 
colon cancer cell lines was well above 10 FM. A concentration 
range of 0.1 - 1 .O PM was used and at 1 .O uM of BIBWZZBS, 
the antiproliferative ffects of 5-fluorouracil were increased 2- to 
6-fold in seven of the eight cell lines. The efficacy of BIBWZZBS 
was clearly dose dependent (Table 2). Four human colon cancer 
cell lines (COLO 205, WiDr, SW1398 and COLO 320) with 
different responses to the combination of BIBWZZBS plus 
5-fluorouracil were selected for the comparison of the potency of 
BIBWZZBS with that of dipyridamole. Again, a concentration 
range of 0.1 - 1.0 FM was studied. From Figure 1, it is clear 
that BIBW22BS enhanced the 5-fluorouracil antiproliferative 
effects to a similar extent to dipyridamole. 
BIBW22BS was then compared with dipyridamole in the 
modulation of the antiproliferative effects of methotrexate and 
gemcitabine, and cell lines of tumours that may be responsive to 
these drugs were included. In MCF-7 and IGROV-1 cells the 
methotrexate antiproliferative effects were slightly increased 
upon the addition of BIBWZZBS and dipyridamole at a concen- 
tration of 1 .O ~.LM. However, a 3-fold increase in the methotrex- 
ate antiproliferative effects was observed in COLO 205 cells 
and the increase appeared to be dose dependent (Figure 1). 
BIBWZZBS was no more effective than dipyridamole in the 
modulation of methotrexate fficacy. In the ovarian cancer cell 
line, A2780, and the two colon cancer cell lines, COLO 205 
and WiDr, the antiproliferative effects of gemcitabine were 
Table 2. BIBW22BS in the modulation of 5-fhmouracil antipro- 
liferative effects in human colon cancer cell lines 
Potentiation factor 5 S.D.* 
Cell line 
BIBWZZBS BIBWZZBS BIBWZZBS 
0.1 /.LM 0.5 PM 1.0 FM 
COLO 205 
WiDr 
SW1398 
LS174T 
COLO 320 
HT29 
LOVO 
SW1116 
4.3 5 2.0 5.9 2 3.5 6.4 k 2.9 
1.6 k 0.2 2.0 -t- 0.3 2.1 2 0.9 
3.5 + 1.0 4.5 ? 1.2 4.8 -’ 1.8 
1.9 + 0.7 2.8 2 1.2 4.2 k 1.8 
1.0 2 0.1 0.9 + 0.1 0.9 + 0.1 
2.4 k 0.5 3.2 ? 1.0 3.7 2 1.2 
1.9 ? 0.3 2.2 k 0.3 2.7 k 0.4 
1.8 + 0.4 3.5 + 1.2 2.9 + 0.7 
*Significant concentration dependence (P i 0.0007, as calculated with 
V\/EzZ). 
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Figure 1. The modulating capacity of 0.1 pM BIBW22BS (O), 
0.1 pM dipyridamole (O), 1.0 pM BIBW22BS (0) or 1.0 pM dipyrid- 
amole (m) on the antiproliferative effects of S-fiuorouracil (SFU), 
methotrexate (MTX) or gemcitabiie (dFdC) in various human cancer 
cell lines. The results are means 2 SD. from at least three separate 
experiments and are expressed as a potentiation or an inhibition 
factor based on the relation between the IC,, of cells treated with drug 
alone and the ICY,, of cells treated with drug and modulator. 
extensively inhibited by BIBWZZBS and dipyridamole in a dose- 
dependent manner. At concentrations of 0.5 and 1.0 ~.LM, the 
antiproliferative ffects of gemcitabine were reduced up to 30- 
fold in COLO 205 and WiDr cells and up to lOO-fold in A2780 
cells (Figure 1). Again, there was no difference in the modulating 
capacity between BIBWZZBS and dipyridamole. 
The COLO 205 cell line was selected to study the influence of 
protein binding because of its high sensitivity to modulation. 
The modulating capacity of BIBW22BS and dipyridamole was 
not reduced when human serum albumin (up to 35 g/l) was 
added to the medium. However, human serum albumin at 
35 g/l resulted in an approximately lo-fold decrease in the 
antiproliferative ffects of 5-fluorouracil alone or in combination 
with BIBWZZBS or dipyridamole (Table 3). Normal human 
serum (up to 40%) added to tissue culture medium, which 
represents approximately 16 g/l human serum albumin, did not 
reduce the modulation capacity of BIBWZZBS or dipyridamole 
(data not shown). 
Dipyridamole has been demonstrated to increase the intra- 
Table 3. The influence of human serum albumin (HSA) on 
antiproliferative effects of 5-jluorouracil in the presence 
BIBW22BS or dipyridamole in COLO 205 cells 
the 
of 
Protein Modulator PF* IV 
Normal culture medium 
HSA 25 g/l 
HSA 35 g/l 
1 PM BIBWZZBS 3.9 -t 0.4 
1 ~~MDipyridamole 3.9 2 0.2 
4.7 + 0.8 
1 /.LM BIBWZZBS 5.5 r 0.9 3.6 + 1.2 
1 ~.LM Dipyridamole 4.6 ? 1.1 4.2 t 0.7 
9.3 ? 3.3 
1 FM BIBWZZBS 5.8 + 1.2 9.0 ? 6.0 
1 )~MDipyridamole 3.3 2 0.8 12.3 5 3.9 
*Potentiation factor (2 S.E.M.) determined by the ratio of the IC,, of 
celis treated with 5-fluorouracil and modulator versus the IC,, of 
cells treated with 5-fluorouracil alone. tkhibition factor (5 S.E.M.) 
determined by the ratio of the IC,, of cells treated in medium with HSA 
versus the IC,, of cells treated inregular medium. 
cellular concentration of FdUMP [13]. Therefore, we measured 
intracellular free FdUMP concentrations in COLO 205, WiDr 
and COLO 320 cells, selected for differences in response to the 
inhibition of nucleoside transport. The assay was carried out five 
times, but levels of free FdUMP were not found to be increased 
after a 4 h incubation of 5-fluorouracil with either BIBWZZBS 
or dipyridamole at 1 .O uM (data not shown). 
In earlier experiments, we found BIBWZZBS to be 20- to lOO- 
fold more potent in the reversal of resistance in Pgp-positive 
human cancer cell lines [5]. Therefore, BIBW22BS was also 
compared with dipyridamole in the potentiation of the antipro- 
liferative effects of vincristine and doxorubicin in two colon 
cancer cell lines, COLO 205 and COLO 320. Both cell lines 
showed a different response to the nucleoside-inhibiting effects 
of BIBWZZBS. COLO 205 cells, which are Pgp-negative, were 
sensitive to the nucleoside-inhibiting effects of BIBWZZBS 
whereas COLO 320 cells, which are Pgp-positive, were insensi- 
tive to the nucleoside-inhibitingeffectsof BIBWZZBS. A concen- 
tration range of 0.1 - 1 .O (*M of both modulators was tested in 
the presence of the anticancer drugs. At 1.0 FM of BIBWZZBS, 
the antiproliferative effects of vincristine and doxorubicin in 
COLO 320 cells were increased 181- and 7.6-fold, respectively 
(Figure 2). Dipyridamole at the same concentration could only 
slightly increase the vincristine antiproliferative effects up to 
7. l-fold (Figure 2). In the Pgp-negative cell line COLO 205, an 
insignificant increase in the antiproliferative ffects of vincristine 
(2-fold), but no change with doxorubicin was observed with 
both modulators at 1 .O FM. 
Since BIBW22BS potentiated the 5-fluorouracil antiprolifer- 
ative effects in COLO 205 and WiDr cells in vitro, we determined 
the modulating capacity of BIBWZZBS on the growth inhibition 
by 5-fluorouracil in corresponding xenografts. In these xeno- 
grafts, BIBWZZBS failed to enhance the antitumour effects of 5- 
fluorouracil (Table 4). However, 5-fluorouracil alone did not 
induce any notable tumour growth inhibition in these xenografts. 
Because of the significant inhibition of the antiproliferative 
effects of gemcitabine by BIBW22BS in A2780 cells, the modu- 
lator was studied in combination with gemcitabine in A2780 
xenografts. Gemcitabine alone inhibited the tumour growth up 
to 99%. BIBWZZBS failed to reduce the antitumour effects of 
gemcitabine. In a separate study, BIBWZZBS was administered 
simultaneously with gemcitabine weekly X 2, but again no 
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Figure 2. The inllueoce of various concentrations of BIBWMBS (m) and dipyridamole (0) on the antiproliferative effects of vincristine (VCR) 
and doxorubicio (DOX) in COLO 320 (Pgp-positive) and COLO 205 (Pgp-negative) colon cancer cell lines. The results are means + S.E.M. 
from at least three separate experiments and are expressed as a poteotiation factor based on the relationship between the ICY,, of cells treated 
with drug alone and the IC, of cells treated with drug and modulator. 
Table 4. The influence of BIB W22BS on the growth inhibition of 
5-fluorouracil (5F.V) or gemcitabine (dFdC) in human twwur 
xenografts 
Drug* BIBWZZBS 
Xenograft i.p. i.v. Days GI%t R.W.L.%$ 
COLO 205 none 50 q7dx4 13% 6.0(-c 3.5) 
5FLJ - q7dx4 28% 5.3 (’ 2.5) 
5FU 50 q7dx4 14% 10.7 (2 1.2) 
WiDr none 50 q7dx4 5% 4.3 (? 3.8) 
5FU - q7dx4 0% 5.8(? 1.6) 
5FU 50 q7dx4 0% 7.1 (2 3.5) 
A2780 none 50 q7dx2 0% O.O(? 1.4) 
dFdC - q7dx2 99%§ 17.8 (2 1.4) 
dFdC 50 q7dx2 99%$ 15.7 (2 3.1) 
*SFU 60 mg/kg weekly x 4 or dFdC 120 mg/kg weekly x 2 preceded 
or not by BIBWZZBS 50 mg/kg with an interval of 1 h. tGrowth 
inhibition expressed as lOO%- T/C%, where TIC% is the optimal value 
of the mean volume in treated tumours/mean of relative volume in 
control tumours x 100%. *Mean relative weight loss when compared to 
day 0 (? S.E.M.). $Significant difference between treated and control 
tumours evaluated with Student’s t-test. q7d, once every 7 days. 
reduction of the tumour growth inhibition was observed (data 
not shown). The combinations of BIBWZZBS and 5-fluorouracil 
or gemcitabine did not cause an increase in weight loss or other 
visible side-effects in the tumour-bearing mice. 
DISCUSSION 
BIBWZZBS, a derivative of dipyridamole, was studied as a 
modulator of nucleoside transport in human cancer cell lines 
varying in the expression of particular drug transport character- 
istics. In seven of the eight colon cancer cell lines tested, 
an increase of the S-fluorouracil antiproliferative effects was 
observed with BIBW22BS in a dose-dependent manner. 
BIBWZZBS also enhanced the activity of niethotrexate, but 
extensively reduced the gemcitabine antiproliferative effects. 
The efficacy of BIBW22BS as a nucleoside transport modulator 
was found to be similar to that of dipyridamole, but BIBW22BS 
was more potent in the reversal of multidrug resistance in a Pgp- 
positive colon cancer cell line. Despite the promising results 
obtained in vitro, BIBWZZBS did not affect growth inhibition of 
either 5-fluorouracil or gemcitabine in human tumour xenografts 
in nude mice. 
In the present experiments, BIBWZZBS and dipyridamole 
were similarly effective in the modulation of the antiproliferative 
effects of 5-fluorouracil. Chen and associates [4] have reported 
that BIBWZZBS at 1.0 PM can enhance the antiproliferative 
effects of 5-fluorouracil in KB cells by approximately 20-fold 
compared to approximately 2-fold in the case of dipyridamole. 
This finding does not agree with our data and this may possibly 
be explained by the higher sensitivity of KB cells to BIBW22BS 
at 1.0 PM, because in the presence of low, non-toxic concen- 
trations of 5-fluorouracil, a 30% cell growth inhibition could 
already be measured. 
The influence of BIBWZZBS on the antiproliferative ffects of 
5-fluorouracil was dose dependent and varied between the eight 
colon cancer cell lines. Grem [l] has studied the possible 
mechanism by which dipyridamole augments the 5-fluorouracil 
antiproliferative effects in the HCT 116 colon cancer cell line. 
In this model cell line, the modulating capacity of the compound 
was found to be based on a selective increase in FdUMP levels 
by blocking the efflux of fluorodeoxyuridine from the cells [ 131. 
Intracellular FdUMP in HCT 116 cells, after exposure to 
dipyridamole and 5-fluorouracil for 4 h, was 5-fold higher when 
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compared to 5fluorouracil exposure alone. The addition of 
thymidine at 25 PM reduced the formation of FdUMP. Alterna- 
tively, deoxyuridine at 25 p,M could enhance the antiproliferat- 
ive effects of 5-fluorouracil in the absence or the presence of 
dipyridamole, which was probably caused by an increase in the 
amount of FdUMP formed [ 141. We did not detect an alteration 
of FdUMP levels in the colon cancer cell lines COLO 205 and 
WiDr in which BIBWZZBS at 1.0 ~.LM could increase the 5- 
fluorouracil antiproliferative effects 6.4- and 2. l-fold, respect- 
ively. It is not likely that the assays used explain the difference, 
as Grem and Fischer [ 131 have detected [6-3H] FdUMP by high- 
performance liquid chromatography (HPLC), while our assay is 
based on the measurement of free binding sites for L. casei 
thymidylate synthase. Both assays use a similar extraction 
procedure and measure levels far above the threshold level. 
Moreover, the enzyme assay is more specific since only one 
metabolite, FdUMP, can bind to thymidylate synthase with 
such high affinity, while HPLC detection of FdUMP is often 
hampered by co-elution of fluorodeoxyuridine [ 131. It may well 
be possible that the inhibition of fluorodeoxyuridine efflux is not 
the only mechanism for the enhanced 5-fluorouracil action, as 
both 5-fluorouracil and dipyridamole were also found to produce 
alkaline labile sites in newly synthesised DNA [ 14, 151. 
As with dipyridamole, BIBWZZBS modulated the antipro- 
liferative effects of other antimetabolites, such as methotrexate 
and gemcitabine. Methotrexate binds strongly to dihydrofolate 
reductase, and thereby produces a depletion of reduced folates, 
which are essential for the synthesis of thymidine monophos- 
phate and purines [16]. In vitro studies have indicated that 
dipyridamole potentiates the antiproliferative effects of metho- 
trexate through inhibition of thymidine salvage [17]. Indeed, 
both BIBW22BS and dipyridamole at 1.0 FM enhanced the 
antiproliferative effects of methotrexate in the three cell lines 
tested. In the case of gemcitabine, an analogue of deoxycytidine, 
both BIBWZZBS and dipyridamole extensively inhibited its 
efficacy in vitro. Gemcitabine is phosphorylated by the enzyme 
deoxycytidine kinase into difluorodeoxycytidine triphosphate 
(dFdCTP). The cytotoxic effect of gemcitabine is associated with 
an inhibition of DNA synthesis by competitive incorporation of 
dFdCTP into the growing DNA strand [18]. The mechanism 
underlying the reduction of the gemcitabine efficacy is not yet 
known, but may be explained by the inhibition of the uptake of 
gemcitabine by facilitated diffusion-mediated membrane trans- 
port into the cells. 
Unfortunately, the in vivo experiments of BIBWZZBS did not 
result in modulation of the antitumour effects of 5-fluorouracil 
or gemcitabine. There are several reasons to explain this finding. 
Firstly, we are not aware of the concentrations and the retention 
time of BIBWZZBS in the three human tumour xenografts 
studied. One may consider the dose and the schedule used in 
these experiments to be suboptimal for obtaining effective 
concentrations of BIBWZZBS in tumour tissue. In addition, 
even in the presence of sufficient BIBWZZBS concentrations 
for nucleoside transport inhibition, tumour growth delay by 
gemcitabine may also occur through passive diffusion. Secondly, 
in patients, dipyridamole is > 95% protein bound, particularly 
to albumin and o,-acid glycoprotein [19, 201. In the in vitro 
study, where human serum albumin (up to 35 g/l) or normal 
human serum (up to 40%) was added to the medium, we did not 
fmd a reduction in the modulating capacity of BIBWZZBS or 
dipyridamole. Protein binding of dipyridamole in normal tissue 
culture medium is low as has been reported by Grem [l]. It 
may be that a,-acid glycoprotein is the major determinant for 
dipyridamole binding, as the nucleoside-inhibiting activity of 
the compound was IO- to 200-fold reduced in the presence of a 
physiological concentration of that protein [2 11. 
Dipyridamole is also known as a compound that can restore 
the sensitivity in Pgp-positive cells expressing the ‘classical’ 
multidrug resistance phenotype [4, 22, 231. As an illustration of 
our earlier experiments [5], we again showed a higher potency 
of BIBWZZBS in the modulation of vincristine and doxorubicin 
resistance in the Pgp-positive COLO 320 cell line when com- 
pared to dipyridamole at an equimolar concentration. 
It can be concluded that BIBWZZBS is more potent than 
dipyridamole in the modulation of multidrug resistance in Pgp- 
positive cells, but both compounds show a similar potency in the 
inhibition of nucleoside transport. Further studies are necessary 
to decide on the clinical usefulness of a bifunctional modulator 
to improve the efficacy of chemotherapy. 
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